ResearcherOregon Health & Science UniversityActive in the last 2 years
Emerson Yu-sheng Chen
Matched on ORCID iD 0000-0003-3035-4478; OpenAlex author ID A5060933822. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2022: 1 paper · 2023: 1 paper · 2024: 1 paper
Papers 3
- CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancer. Co-author DOI 10.1080/14796694.2024.2395235↗
- Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic… Co-author DOI 10.1002/cam4.5971↗
- Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resection in Pancreatic Cancer without Increasin… Co-author DOI 10.3390/cancers14030609↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Brett C. Sheppard · 3 shared papers, 2022–2024 · strength 0.41
- Paper CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancer. DOI 10.1080/14796694.2024.2395235↗
- Paper Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderlin… DOI 10.1002/cam4.5971↗
- Paper Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resectio… DOI 10.3390/cancers14030609↗
- Adel Kardosh · 3 shared papers, 2022–2024 · strength 0.41
- Paper CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancer. DOI 10.1080/14796694.2024.2395235↗
- Paper Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderlin… DOI 10.1002/cam4.5971↗
- Paper Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resectio… DOI 10.3390/cancers14030609↗
- Charles D. Lopez · 3 shared papers, 2022–2024 · strength 0.41
- Paper CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancer. DOI 10.1080/14796694.2024.2395235↗
- Paper Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderlin… DOI 10.1002/cam4.5971↗
- Paper Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resectio… DOI 10.3390/cancers14030609↗
- Aaron J. Grossberg · 2 shared papers, 2022–2023 · strength 0.26
- Paper Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderlin… DOI 10.1002/cam4.5971↗
- Paper Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resectio… DOI 10.3390/cancers14030609↗
- Skye C. Mayo · 2 shared papers, 2022–2023 · strength 0.26
- Paper Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderlin… DOI 10.1002/cam4.5971↗
- Paper Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resectio… DOI 10.3390/cancers14030609↗
- Charles R. Thomas · 2 shared papers, 2022–2023 · strength 0.26
- Paper Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderlin… DOI 10.1002/cam4.5971↗
- Paper Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resectio… DOI 10.3390/cancers14030609↗
- Zeev A. Ronai · 1 shared paper, 2024 · strength 0.15
- Gordon Brent Mills · 1 shared paper, 2024 · strength 0.15
- Alexander Savio Ramos Guimaraes · 1 shared paper, 2024 · strength 0.15
- Rosalie C. Sears · 1 shared paper, 2024 · strength 0.15
- Jonathan Robert Brody · 1 shared paper, 2024 · strength 0.15
- Gina M. Vaccaro · 1 shared paper, 2023 · strength 0.15
- Ali Noel Gunesch · 1 shared paper, 2022 · strength 0.11
- Christopher R. Deig · 1 shared paper, 2022 · strength 0.11
- Thomas Lee Sutton · 1 shared paper, 2022 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.